Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

158.25 +0.71 (+0.45%)
Official Closing Price Updated: 7:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
 
Via Benzinga
2 Relatively Safe Dividend Stocks You Won't Regret Owning
They're both ready to continue paying a dividend that grows year after year. 
Via The Motley Fool
This Is the Best Dividend ETF You Can Buy
ETFs provide stability and diversification to a portfolio. 
Via The Motley Fool
Is Big Pharma Coming For Your Cannabis Business?
Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies... 
Via Benzinga
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Better Buy: AbbVie vs. Johnson & Johnson
These pharma giants beat the bear market last year. 
Via The Motley Fool
AbbVie Unusual Options Activity
 
Via Benzinga
2 Reasons to Buy AbbVie, and 1 Reason to Sell
AbbVie shares rose in the double digits last year. 
Via The Motley Fool
I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.
It isn't an easy decision to choose the best among this group of dividend stocks. 
Via The Motley Fool
This Delivery Giant Is A 'Comeback Story' Plus Nike, AbbVie And Oracle: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named AbbVie Inc. (NYSE: ABBV) 
Via Benzinga
3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence
Your stock screening and research process will never be the same. 
Via The Motley Fool
2 High-Yield Dividend Stocks You Won't Regret Buying Right Now
These two blue-chip dividend stocks offer investors a reliable income stream in a volatile market. 
Via The Motley Fool
Use These 3 Strategies to Make $1,000 in Passive Income Per Year
It's worth having these approaches in your investor toolkit. 
Via The Motley Fool
Price Over Earnings Overview: AbbVie
 
Via Benzinga
This Is What Whales Are Betting On AbbVie
 
Via Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
 
Via Benzinga
AbbVie Provides Regulatory Update On Parkinson's Disease Drug Candidate
AbbVie Inc (NYSE: ABBV) provided a regulatory update on its New Drug Application (NDA) for  
Via Benzinga
These 3 Dividend Growers Yield More Than the 10-Year Note
Dividend aristocrats with yields greater than the 10-year note yield plus the potential for price appreciation could be a winning formula in this environment. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
4 Top Value Stock ETFs for Long-Term Wealth Building
It could be value's time to shine for the first time in years. 
Via The Motley Fool
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
It's still unclear whether CMS will include those drugs in its negotiation list. 
Via Investor's Business Daily
2 Growth Stocks to Buy Before the Bull Market Arrives
Long-term investors shouldn't hesitate to add these stocks to their portfolios. 
Via The Motley Fool
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly... 
Via Benzinga
Healthcare Stocks With at Least 30 Years of Dividend Increases
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. 
Via MarketBeat
Oracle, AbbVie And This Gold Fund: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Oracle Corporation (NYSE: ORCL) as his pick. 
Via Benzinga
Dividend Income Update February 2023
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
5 Forever Dividend Stocks
These five dividend stocks make it a priority to return money to shareholders. 
Via The Motley Fool
Diversify Your Income with These 2 High-Yielding Dividend ETFs
Diversification is a term widely used when it comes to investing in the stock market. It means spreading your investment across different sectors and indust 
Via MarketBeat
Topics ETFs
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
 
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in March
Going with these great dividend stocks is an easy choice. 
Via The Motley Fool
Reap Monthly Income With This Combination Of 3 Stocks
While the majority of stocks pay quarterly dividends, investors can still construct a portfolio that allows them to get paid monthly. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.